semaglutide iih Idiopathic Intracranial Hypertension and the Challenge of Weight Loss NeuroOp Guru: Stopping GLP-1 therapy

Previous studies have suggested that lean body mass including muscle can constitute up to 40% of total weight lost during treatment

These reports documented: Severe gastroparesis requiring hospitalization and ongoing medical treatment Intestinal blockages necessitating emergency surgery Vision loss cases involving non-arteritic anterior ischemic optic neuropathy Deep vein thrombosis and other cardiovascular complications Gallbladder disease requiring surgical removal Rather than immediately updating Ozempics warning label to reflect these serious concerns, pharmaceutical companies continued aggressive marketing of the weight loss drug

The Triple-Agonist Changing Weight Loss in 2026 Retatrutide is the most powerful weight loss peptide in 2026 a triple-agonist targeting GLP-1, GIP, and glucagon

Semaglutide and other GLP-1 agonistsmedications that bind to GLP-1 receptors and mimic their effectsare currently used as treatments for diabetes and obesity